Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 13/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 13/20 | 0.38 |
| ▸ | GSK3B | P49841 | 11/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706147 | 0.89 | BRAF (0.44) | RHOABRAFCNR2CNR1 | |
| SCHEMBL19670539 | 0.89 | BRAF (0.37) | RHOABRAFCNR2GRM5CNR1 | |
| SCHEMBL19706131 | 0.85 | POLB (0.42) | BRAFCNR2GRM5 | |
| SCHEMBL19365660 | 0.85 | DYRK1A (0.37) | RHOABRAFWNT1DYRK1AGSK3B | |
| SCHEMBL17618833 | 0.82 | RHOA (0.38) | RHOABRAFWNT1DYRK1AGSK3B | |
| SCHEMBL19670657 | 0.82 | MPL (0.42) | CNR2GRM5 | |
| SCHEMBL16776379 | 0.79 | WNT1 (0.39) | RHOABRAFWNT1DYRK1AGSK3B | |
| SCHEMBL19706127 | 0.79 | TSHR (0.47) | GSK3BCNR2GRM5 | |
| SCHEMBL19706268 | 0.78 | RHOA (0.46) | RHOABRAF | |
| SCHEMBL19670658 | 0.78 | KDM1A (0.38) | RHOABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RHOA 4798/4885BRAF 3419/4885WNT1 3363/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | RHOA 4798/4885BRAF 3419/4885WNT1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.